Ozempic And Wegovy: How 2 Diabetes Medications Became The Most Popular Weight-loss Drugs Most Innovative Companies podcast

Artwork

Tech Business Mansueto Ventures Fast Company MBA

Contenido proporcionado por Mansueto Ventures and Fast Company. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Mansueto Ventures and Fast Company o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

Most Innovative Companies « »
Ozempic and Wegovy: How 2 diabetes medications became the most popular weight-loss drugs

10M ago 57:14

Compartir

MP3•Episodio en casa

Contenido proporcionado por Mansueto Ventures and Fast Company. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Mansueto Ventures and Fast Company o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

In the United States, nearly three-quarters of adults qualify as overweight or obese, 42% of whom are considered obese. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035.

‘Fast Company’ contributing writer Adam Bluestein joined us to break down how Novo Nordisk, the company behind Ozempic and Wegovy, developed and marketed its weight-loss drugs. He also explained why the drugs have become so popular in the U.S., how drug pricing is extremely complicated and . . . how the medications actually work to help people lose weight.

Also, we chatted with Trina Spear about how she founded Figs, a DTC healthcare apparel company.

… continue reading

112 episodios

#Tech #Business #Mansueto Ventures #Fast Company #MBA

Artwork

Ozempic and Wegovy: How 2 diabetes medications became the most popular weight-loss drugs

Most Innovative Companies

14 subscribers

published 10M ago

Compartir

MP3•Episodio en casa

Contenido proporcionado por Mansueto Ventures and Fast Company. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Mansueto Ventures and Fast Company o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

In the United States, nearly three-quarters of adults qualify as overweight or obese, 42% of whom are considered obese. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035.

‘Fast Company’ contributing writer Adam Bluestein joined us to break down how Novo Nordisk, the company behind Ozempic and Wegovy, developed and marketed its weight-loss drugs. He also explained why the drugs have become so popular in the U.S., how drug pricing is extremely complicated and . . . how the medications actually work to help people lose weight.

Also, we chatted with Trina Spear about how she founded Figs, a DTC healthcare apparel company.

… continue reading

112 episodios

#Tech #Business #Mansueto Ventures #Fast Company #MBA

Todos los episodios

×

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

Escucha más de 500 temas